ZIA BC 010940 (ZIA) | |||
---|---|---|---|
Title | Cutaneous Adverse Drug Reactions | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Kong, Heidi | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $10,099 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2016 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) | Melanoma (100.0%) | ||
Research Type | |||
Resources and Infrastructure Related to Treatment and the Prevention of Recurrence Patient Care and Survivorship Issues |
|||
Abstract | |||
We have continued to evaluate oncology patients at risk for the development of cutaneous toxicities associated with molecularly targeted therapies. These evaluations include baseline evaluations prior to initiation of treatment and follow-up visits to monitor and treat these skin toxicities. We previously have worked and continue to work with oncology colleagues a) to optimally design treatment protocols to evaluate for and treat cutaneous toxicities, and b) to inform the research community of potentially newly described skin toxicities and methods for management of these adverse effects to optimize continued antineoplastic treatment of oncology patients through multiple peer-reviewed publications and lectures intramurally and extramurally. |